Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer
Launched by BOEHRINGER INGELHEIM · Mar 28, 2011
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion criteria:
- • 1. Female patients \>=18 years with proven diagnosis of HER2-overexpressing, histologically confirmed breast cancer
- • 2. Locally advanced or metastatic disease
- • 3. Must have disease that can be evaluated according to RECIST 1.1 (Response Evaluation Criteria for Solid Tumours version 1.1)
- • 4. For trastuzumab pre-treated patients, must have failed prior trastuzumab treatment
- • 5. Investigator-confirmed diagnosis of Inflammatory Breast Cancer
- • 6. Must have biopsiable disease
- Exclusion criteria:
- • 1. Prior treatment with HER2-targeted small molecules or antibodies other than trastuzumab (which must have been given in the trastuzumab-failure study population)
- • 2. Must not have received prior vinorelbine treatment
About Boehringer Ingelheim
Boehringer Ingelheim is a global, research-driven pharmaceutical company dedicated to improving health and quality of life through innovative therapies. Established in 1885 and headquartered in Ingelheim, Germany, the company focuses on the development of prescription medicines in key therapeutic areas, including respiratory diseases, cardiovascular health, oncology, and immunology. Boehringer Ingelheim is committed to advancing medical science through rigorous clinical trials and collaborative research, striving to bring novel treatments to patients while upholding the highest standards of safety and efficacy. With a strong emphasis on sustainability and corporate responsibility, the company aims to make a meaningful impact on global health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Durham, North Carolina, United States
East Bentleigh, Victoria, Australia
Perth, Western Australia, Australia
Hong Kong, , Hong Kong
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Bangkok, , Thailand
Bangkok, , Thailand
Chiangmai, , Thailand
Hat Yai, Songkhla, , Thailand
Ariana, , Tunisia
Sousse, , Tunisia
Bournemouth, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Patients applied
Trial Officials
Boehringer Ingelheim
Study Chair
Boehringer Ingelheim
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials